AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18289194 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment with esomeprazole 40 mg once daily for 4 weeks
Number of subjects: 612
Study 18289194 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy-oriented treatment (esomeprazole 40 mg od for reflux esophagitis, esomeprazole 20 mg od for no esophagitis) for 4 weeks
Number of subjects: 612
Study 18289194 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment with esomeprazole 20 mg od maintenance treatment after 4 weeks
Number of subjects: 612
Study 18289194 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy-oriented treatment with esomeprazole 20 mg od maintenance treatment after 4 weeks
Number of subjects: 612
Study 18289194 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment with esomeprazole
Number of subjects: 612
Study 18289194 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy-oriented treatment
Number of subjects: 612
Study 17052416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg in 2mls)
Number of subjects: 60
Study 17052416 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo, 2 mls)
Number of subjects: 60
Study 14983991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered protocol (NP)
Number of subjects: 473
Study 14983991 — intervention group
Group type: COMPARATOR
Intervention: Traditional physician reminder (PR)
Number of subjects: 473
Study 14983991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NP and PR groups
Number of subjects: 473
Study 10851773 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentian violet topical application
Number of subjects: 39
Study 10851773 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing (control)
Number of subjects: 39
Study 10851773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 39
Study 8656090 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIVA
Number of subjects: 148
Study 8656090 — intervention group
Group type: COMPARATOR
Intervention: stripping
Number of subjects: 148
Study 1905472 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet of high biological value (20-30 g/day) and high calorie content (3000 kcal/day) for 18 to 28 months
Number of subjects: 12
Study 1905472 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted protein intake (40-60 g/day)
Number of subjects: 12
Study 1905472 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis of serum creatinine values against time
Number of subjects: 12
Study 6140023 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium 0.75, 1.0, 1.25 mg kg‐1
Number of subjects: 64
Study 6140023 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 64
Study 6140023 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium and Pancuronium
Number of subjects: 64
Study 30918032 — intervention group
Group type: EXPERIMENTAL
Intervention: mupirocin plus aFGF
Number of subjects: 120
Study 30918032 — intervention group
Group type: COMPARATOR
Intervention: mupirocin plus placebo
Number of subjects: 120
Study 30113199 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care model featuring psychological and physical interventions
Number of subjects: 179
Study 30113199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluctuating higher-risk group
Number of subjects: 179
Study 27734772 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenges
Number of subjects: 204
Study 27734772 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 204
Study 24714767 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic white spirits (aWS) at 100 mg/m(3)
Number of subjects: 12
Study 24714767 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic white spirits (aWS) at 300 mg/m(3)
Number of subjects: 12
Study 24714767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dearomatized white spirits (daWS) at 100 mg/m(3)
Number of subjects: 12
Study 24714767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dearomatized white spirits (daWS) at 300 mg/m(3)
Number of subjects: 12
Study 24714767 — intervention group
Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 12
Study 22259068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists with more information resources
Number of subjects: 344
Study 22259068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists with a sense of responsibility to discuss fertility issues
Number of subjects: 344
Study 22259068 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecologic oncologists
Number of subjects: 344
Study 22259068 — intervention group
Group type: COMPARATOR
Intervention: Physician age, gender, and practice setting
Number of subjects: 344
Study 19062091 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose imatinib (600-800 mg daily)
Number of subjects: 0
Study 19062091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose (intermittent or pulsed) maintenance therapy
Number of subjects: 0
Study 17932364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat/low-glycemic load diet (<20% energy from fat and total daily glycemic load <100)
Number of subjects: 8
Study 17932364 — intervention group
Group type: COMPARATOR
Intervention: Standard American diet (approximately 35% energy from fat and total daily glycemic load >200)
Number of subjects: 8
Study 15534356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine and daunorubicin (AD)
Number of subjects: 490
Study 15534356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine and escalated doses of daunorubicin and etoposide +/- PSC-833 (ADE/ADEP)
Number of subjects: 490
Study 15534356 — intervention group
Group type: EXPERIMENTAL
Intervention: One cycle of high-dose cytarabine (HDAC) followed by etoposide/cyclophosphamide and mitoxantrone/diaziquone (group I)
Number of subjects: 490
Study 15534356 — intervention group
Group type: EXPERIMENTAL
Intervention: Three HDAC cycles (group II)
Number of subjects: 490
Study 15534356 — intervention group
Group type: EXPERIMENTAL
Intervention: Four intermediate-dose cytarabine (IDAC) or HDAC cycles (group III)
Number of subjects: 490
Study 15534356 — intervention group
Group type: EXPERIMENTAL
Intervention: One HDAC/etoposide cycle and autologous stem-cell transplantation (ASCT; group IV)
Number of subjects: 490
Study 11965510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron supplementation (4800 RE vitamin A, 120 mg iron, and 500 microg folic acid)
Number of subjects: 0
Study 11965510 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation (120 mg iron and 500 microg folic acid)
Number of subjects: 0
Study 11965510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron supplementation
Number of subjects: 0
Study 11965510 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation
Number of subjects: 0
Study 9808874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylephrine 75 mg/die
Number of subjects: 169
Study 9808874 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg/die
Number of subjects: 169
Study 9808874 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group A)
Number of subjects: 169
Study 8620236 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on pediatric health care issues
Number of subjects: 130
Study 8620236 — intervention group
Group type: COMPARATOR
Intervention: Usual PED discharge instructions (Control)
Number of subjects: 130
Study 2674593 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg‐1) administered 60 min prior to exercise
Number of subjects: 6
Study 2674593 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg‐1)
Number of subjects: 6
Study 807952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methotrexate followed by radical irradiation
Number of subjects: 96
Study 807952 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 96
Study 30112756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate (MgSO4)
Number of subjects: 0
Study 30112756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30112756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate (MgSO4) in males
Number of subjects: 0
Study 30112756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate (MgSO4) in females
Number of subjects: 0
Study 28141698 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5mp
Number of subjects: 1014
Study 28141698 — intervention group
Group type: COMPARATOR
Intervention: RV5
Number of subjects: 1014
Study 25402222 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related cognitive-behavioral treatment (W-CBT)
Number of subjects: 26
Study 25402222 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment as usual (CBT-AU)
Number of subjects: 26
Study 24432676 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to SSRIs
Number of subjects: 60
Study 24432676 — intervention group
Group type: COMPARATOR
Intervention: SSRIs only (Control)
Number of subjects: 60
Study 21503375 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on obesity
Number of subjects: 300
Study 21503375 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 300
Study 19386609 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin infusion alone for 5 days
Number of subjects: 93
Study 19386609 — intervention group
Group type: EXPERIMENTAL
Intervention: Banding ligation plus terlipressin infusion for 2 days
Number of subjects: 93
Study 16878187 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (50 microg/kg)
Number of subjects: 26
Study 16878187 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (2 mg/kg) plus dimenhydrinate (5 mg/kg)
Number of subjects: 26
Study 15107313 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused educational programme on nutrition over one school year
Number of subjects: 644
Study 15107313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 644
Study 11736727 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole-based therapy (10 mg rabeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Number of subjects: 173
Study 11736727 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day rabeprazole-based therapy (20 mg rabeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Number of subjects: 173
Study 11736727 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day omeprazole-based therapy (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Number of subjects: 173
Study 9414057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Education Program
Number of subjects: 313
Study 8214728 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol (BU) 3 mg
Number of subjects: 102
Study 8214728 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (MS)
Number of subjects: 102
Study 8214728 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural nalbuphine (NB) 10 mg
Number of subjects: 102
Study 8214728 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone (NX) 6 mg
Number of subjects: 102
Study 3101895 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 30
Study 3101895 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 30
Study 31490239 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential negative pressure (125 mm Hg) applied to the midarm for 9 hours
Number of subjects: 13
Study 31490239 — intervention group
Group type: COMPARATOR
Intervention: Control: Same device without negative pressure applied to the contralateral midarm
Number of subjects: 13
Study 31490239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control
Number of subjects: 13
Study 29716655 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg once daily for the first 6 weeks, then 10 mg once daily for the next 6 weeks)
Number of subjects: 18
Study 29716655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29716655 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 18
Study 29278472 — intervention group
Group type: EXPERIMENTAL
Intervention: MV+QL
Number of subjects: 60
Study 29278472 — intervention group
Group type: COMPARATOR
Intervention: MV
Number of subjects: 60
Study 24403544 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine booster
Number of subjects: 250
Study 24403544 — intervention group
Group type: COMPARATOR
Intervention: No Hib conjugate vaccine booster
Number of subjects: 250
Study 22405683 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 21)
Number of subjects: 41
Study 22405683 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (n = 20)
Number of subjects: 41
Study 22405683 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 41
Study 22405683 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 41
Study 20595196 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanomyography
Number of subjects: 40
Study 20595196 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromyography
Number of subjects: 40
Study 20595196 — intervention group
Group type: COMPARATOR
Intervention: Normalization during recovery
Number of subjects: 40
Study 18540741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session exposure-based treatment plus inactive pill with sedating herb description
Number of subjects: 95
Study 18540741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session exposure-based treatment plus inactive pill with stimulating herb description
Number of subjects: 95
Study 18540741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session exposure-based treatment plus inactive pill with placebo description
Number of subjects: 95
Study 18540741 — intervention group
Group type: COMPARATOR
Intervention: 1-session exposure-based treatment
Number of subjects: 95
Study 18540741 — intervention group
Group type: COMPARATOR
Intervention: waitlist condition
Number of subjects: 95
Study 18540741 — intervention group
Group type: COMPARATOR
Intervention: psychological placebo condition
Number of subjects: 95
Study 16106480 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP operation
Number of subjects: 1183
Study 16106480 — intervention group
Group type: COMPARATOR
Intervention: Shouldice operation
Number of subjects: 1183
Study 11988412 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive and childhood social class variables
Number of subjects: 46
Study 10082241 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK4 (25 microg, i.v. injection)
Number of subjects: 16
Study 10082241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8851038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once a day
Number of subjects: 254
Study 8851038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 2261015 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 0.1% cream with Duoderm dressing
Number of subjects: 23
Study 2261015 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 0.1% cream with Actiderm dressing
Number of subjects: 23
Study 366723 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg to 375 mg twice daily
Number of subjects: 30
Study 366723 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 500 mg to 750 mg four times daily
Number of subjects: 30
Study 366723 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 30
Study 366723 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 30
Study 31931888 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised pneumoperitoneum pressure strategy
Number of subjects: 0
Study 31931888 — intervention group
Group type: COMPARATOR
Intervention: Conventional pneumoperitoneum pressure strategy
Number of subjects: 0
Study 31260678 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg prednisolone/d for 5 days
Number of subjects: 9
Study 31260678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 27442717 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded motor imagery (GMI)
Number of subjects: 28
Study 27442717 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (Control)
Number of subjects: 28
Study 26025033 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate 1%
Number of subjects: 67
Study 26025033 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1%
Number of subjects: 67
Study 26025033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 23485142 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat crackers
Number of subjects: 0
Study 23485142 — intervention group
Group type: COMPARATOR
Intervention: Rice crackers
Number of subjects: 0
Study 23485142 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat crackers (daily for 1 week)
Number of subjects: 0
Study 21883530 — intervention group
Group type: EXPERIMENTAL
Intervention: Two fruit and nut bars totalling 1421.9 kJ (340 kcal) added to ad libitum diet
Number of subjects: 94
Study 18178245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (CHIP program)
Number of subjects: 348
Study 18178245 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 348
Study 17095445 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional education
Number of subjects: 0
Study 15344469 — intervention group
Group type: EXPERIMENTAL
Intervention: Permutation tests for classification in image-based studies
Number of subjects: 0
Study 15344469 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing on a hold-out set or cross-validation
Number of subjects: 0
Study 10710121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/day)
Number of subjects: 40
Study 10710121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9106315 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (Cloward technique)
Number of subjects: 81
Study 9106315 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 81
Study 9106315 — intervention group
Group type: COMPARATOR
Intervention: Cervical collar
Number of subjects: 81
Study 9106315 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Surgery, Physiotherapy, Cervical collar)
Number of subjects: 81
Study 1540093 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 500-mg suspension every 8 hours, and nystatin, 1 million units every 6 hours
Number of subjects: 46
Study 1540093 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo solutions administered through a nasogastric tube
Number of subjects: 46
Study 3895383 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopists with knowledge of the radiological diagnosis
Number of subjects: 156
Study 3895383 — intervention group
Group type: COMPARATOR
Intervention: Endoscopists without knowledge of the radiological diagnosis
Number of subjects: 156
Study 30461166 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised interpretation of fetal heart rate patterns
Number of subjects: 46614
Study 29706169 — intervention group
Group type: EXPERIMENTAL
Intervention: PNC-txt (text message-delivered Peer Network Counseling)
Number of subjects: 30
Study 29706169 — intervention group
Group type: COMPARATOR
Intervention: Control (waitlist)
Number of subjects: 30
Study 25761488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² intravenously every 3 weeks
Number of subjects: 95
Study 25761488 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg/day orally
Number of subjects: 95
Study 24651208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic osteotomy (OT) - 6 patients
Number of subjects: 19
Study 24651208 — intervention group
Group type: EXPERIMENTAL
Intervention: No pelvic osteotomy (no-OT) - 13 patients
Number of subjects: 19
Study 24651208 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 19
Study 21850515 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice over treatment options (two pain-relieving treatments, same inert ointment mixture)
Number of subjects: 0
Study 21850515 — intervention group
Group type: EXPERIMENTAL
Intervention: No choice over treatment options (two pain-relieving treatments, same inert ointment mixture)
Number of subjects: 0
Study 21850515 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no treatment expectation)
Number of subjects: 0
Study 19800671 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCNL
Number of subjects: 165
Study 19800671 — intervention group
Group type: COMPARATOR
Intervention: PCNL
Number of subjects: 165
Study 16503029 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon prosthesis (Fluoroplastic piston)
Number of subjects: 138
Study 16503029 — intervention group
Group type: COMPARATOR
Intervention: Schuckneckt type piston wire/Teflon prosthesis
Number of subjects: 138
Study 14642291 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 1 - Children responded to a target within geometric categories, with varying locations.
Number of subjects: 0
Study 14642291 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 2 - Multiple targets placed within each category at the same locations as Experiment 1.
Number of subjects: 0
Study 14642291 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 3 - Children responded to one target more frequently than others.
Number of subjects: 0
Study 10930905 — intervention group
Group type: COMPARATOR
Intervention: OAC (omeprazole 20 mg, amoxycillin 1500 mg, clarithromycin 600 mg for 7 days)
Number of subjects: 106
Study 10930905 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC + CET (OAC plus cetraxate 600 mg for 7 days)
Number of subjects: 106
Study 9283508 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched services (at least 3 professional sessions directed at important employment, family, or psychiatric problems)
Number of subjects: 94
Study 9283508 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (treated in the usual manner)
Number of subjects: 94
Study 8436150 — intervention group
Group type: EXPERIMENTAL
Intervention: isradipine SRO 5 mg once daily
Number of subjects: 37